ZEISS and Alpenglow Biosciences announced a new partnership
ZEISS and Alpenglow Biosciences today announced a new partnership to jointly develop an inverted light-sheet microscope and bioinformatics pipeline tailored specifically for clinical applications.
Alpenglow, a pioneering 3D spatial biology company specializing in open-top light-sheet microscopy, data processing, and AI-driven analysis for biopharma and clinical applications, has partnered with ZEISS, a global leader in light-sheet imaging technologies and visualization software – including ZEISS Lattice Lightsheet 7 and arivis software.
By combining the industry-leading technologies of Alpenglow and ZEISS, the collaboration will enable the broader adoption of 3D pathology across research, translational and clinical applications.
The partnership will create the fastest whole tissue imaging solution by combining exacting engineering and arivis visualization platform from ZEISS with Alpenglow’s innovative data processing and AI capabilities. Once imaged, a GPU-accelerated imaging analytics pipeline could allow users to go from tissue to clinically impactful insights at the same time or faster than traditional pathology workflows.
The generation of 3D images from entire tissues provides the perfect substrate for AI to make individualized treatment predictions for patients. Ultimately, these innovative technologies will deliver tools that streamline pathology workflows and enable earlier, more accurate clinical decision-making.
"Partnering with ZEISS represents a significant step forward in our mission to revolutionize pathology by extracting and analyzing the wealth of information contained in every single cell of a biopsy, rather than relying on just a small fraction of the tissue," said Dr. Nicholas Reder, CEO of Alpenglow Biosciences. "ZEISS’s long-standing history of innovation in light-sheet microscopy is the perfect complement to our cutting-edge software and AI capabilities. Together, we will innovate and expand our existing 3D pathology platform that not only advances the needs of biopharma but also transforms clinical practice."
